Aurobindo Pharma Ltd.
NSE: AUROPHARMA | BSE: 524804
₹1,424.30
₹1.90
(0.13%)
As on 18-Jun-2026 10:19IST
Market cap
₹81,824 Cr
Revenue (TTM)
₹33,653 Cr
P/E Ratio
23.3
P/B Ratio
2.2
Div. Yield
0.3 %
Quality Score
6/10
Growth Score
6/10
Valuation Score
5/10
Momentum Score
9/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹3,505 Cr
-
ROE
11.1 %
-
ROCE
14.4 %
-
Industry P/E
34.2
-
EV/EBITDA
10.9
-
Debt to Equity
0
-
Book Value
₹658.5
-
EPS
₹61.1
-
Face value
1
-
Shares outstanding
575,377,895
10 Years Aggregate
CFO
₹29,776.53 Cr
EBITDA
₹45,072.77 Cr
Net Profit
₹28,517.00 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aurobindo Pharma
| 20.4 | -5.8 | 10.8 | 28.4 | 27.8 | 8.2 | 6.9 |
|
BSE Healthcare
| 9.0 | 0.3 | 11.4 | 9.1 | 23.6 | 13.7 | 12.3 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Aurobindo Pharma
| -12.6 | 23.5 | 147.3 | -40.3 | -20.8 | 101.1 | -37.7 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aurobindo Pharma
|
1,424.3 | 81,824.5 | 33,653.1 | 3,501.5 | 14.9 | 9.7 | 23.3 | 2.2 |
| 26,150.0 | 55,143.7 | 6,929.1 | 1,552.0 | 26.2 | 35.3 | 35.5 | 11.6 | |
| 5,372.0 | 63,929.6 | 14,712.3 | 2,353.1 | 17.8 | 17.7 | 27.8 | 4.6 | |
| 413.6 | 66,732.8 | 16,927.0 | 368.8 | 8.8 | -0.6 | 173.1 | 2.0 | |
| 2,198.8 | 37,249.9 | 3,821.7 | 1,036.0 | 32.5 | 48.8 | 36 | 16.3 | |
| 1,538.1 | 39,026.1 | 9,646.3 | 1,191.4 | 16.2 | 15.5 | 34.2 | 4.8 | |
| 2,281.1 | 1,03,645.5 | 27,958.0 | 5,355.5 | 26.6 | 27.4 | 19.4 | 4.6 | |
| 2,386.7 | 97,611.6 | 14,277.6 | 1,926.4 | 19.1 | 12.8 | 51 | 6.0 | |
| 1,820.7 | 4,36,667.0 | 58,462.0 | 11,564.5 | 23.9 | 15.4 | 38 | 5.2 | |
| 1,078.5 | 1,06,811.7 | 27,148.4 | 5,026.4 | 21.9 | 20.7 | 21.2 | 3.9 |
Shareholding Pattern
View DetailsNews & Analysis
All News
6 min read•By Yash Rohra
4 min read•By Jugal Harpalani
1 min read•By Research Desk
2 min read•By Mohammed Ekramul Haque
About Aurobindo Pharma
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers... formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India. Read more
-
Incorporated
1986
-
Chairman
Mangalam Ramasubramanian Kumar
-
Managing Director
K Nityananda Reddy
-
Group
Aurobindo
-
Headquarters
Hyderabad, Telangana
-
Website
Looking for more details about Aurobindo Pharma Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Aurobindo Pharma
What is the current share price of Aurobindo Pharma Ltd Today?
The share price of Aurobindo Pharma Ltd is ₹1,424.30 (NSE) and ₹1,423.60 (BSE) as of 18-Jun-2026 10:19 IST. Aurobindo Pharma Ltd has given a return of 27.78% in the last 3 years.
What is the current PB & PE ratio of Aurobindo Pharma Ltd?
The P/E ratio of Aurobindo Pharma Ltd is 23.35 times as on 17-Jun-2026, a 32 discount to its peers’ median range of 34.20 times.
The P/B ratio of Aurobindo Pharma Ltd is 2.16 times as on 17-Jun-2026, a 55 discount to its peers’ median range of 4.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
19.32
|
2.06
|
|
2024
|
20.12
|
2.14
|
|
2023
|
15.75
|
1.13
|
|
2022
|
14.80
|
1.59
|
|
2021
|
9.68
|
2.36
|
What is the 52 Week High and Low of Aurobindo Pharma Ltd?
The 52-week high and low of Aurobindo Pharma Ltd are Rs 1,550.00 and Rs 1,016.10 as of 18-Jun-2026.
What is the market cap of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd has a market capitalisation of ₹ 81,824 Cr as on 17-Jun-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Aurobindo Pharma Ltd?
Before investing in Aurobindo Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.